Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
November 03 2020 - 8:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at the 29th Annual Credit Suisse Virtual Healthcare
Conference on Tuesday, November 10, 2020, at 11:45 a.m. ET.
A live webcast of the presentation will be
accessible from the Investors page of Galera’s website,
investors.galeratx.com. An archived version of the webcast will be
available in the News & Events section of the Investors page of
Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer. Galera’s lead
product candidate is avasopasem manganese (GC4419), a highly
selective small molecule superoxide dismutase (SOD) mimetic
initially being developed for the reduction of radiation-induced
severe oral mucositis (SOM). Avasopasem is being studied in the
Phase 3 ROMAN trial to assess its ability to reduce the incidence
and severity of SOM induced by radiotherapy in patients with
locally advanced head and neck cancer (HNC), its lead indication.
It is also being studied in a Phase 2a multi-center trial in Europe
assessing the safety of avasopasem in patients with HNC undergoing
standard-of-care radiotherapy, a Phase 2a trial to assess its
ability to reduce the incidence of esophagitis induced by
radiotherapy in patients with lung cancer, and a Phase 2 trial in
hospitalized patients who are critically ill with COVID-19. A pilot
Phase 1/2 trial of avasopasem in combination with stereotactic body
radiation therapy (SBRT) in patients with locally advanced
pancreatic cancer was completed. The FDA granted Fast Track and
Breakthrough Therapy designations to avasopasem for the reduction
of SOM induced by radiotherapy. Galera’s second SOD mimetic product
candidate, GC4711, is initially being developed to augment the
anti-cancer efficacy of radiation and is currently being studied in
a Phase 1/2 clinical trial in combination with SBRT in patients
with non-small cell lung cancer. Galera is headquartered in
Malvern, PA. For more information, please
visit www.galeratx.com.
Investor Contacts:Christopher
DegnanGalera Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Jennifer PorcelliSolebury
Trout646-378-2962jporcelli@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024